ASCO Ovarian Cancer Guidelines, Mammo-50 Breast Cancer Surveillance, and NRG1 Fusion Therapy Advances

Love what you hear? Download the Curie app from the App Store today.Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.In this episode of Curie, Matt breaks down three major updates in oncology. ASCO has released updated guidelines for advanced ovarian cancer, emphasizing primary cytoreductive surgery over neoadjuvant chemotherapy when feasible. The Mammo-50 trial challenges the standard of annual mammographic surveillance for breast cancer survivors over 50, showing that less frequent screening is non-inferior. Finally, the eNRGy trial confirms the efficacy of zenocutuzumab in treating NRG1 fusion-positive cancers, a rare but actionable oncogenic driver in NSCLC and pancreatic cancer. Tune in for expert insights into how these findings are shaping cancer care.